Jörg Schilling1, Christian M Kurbacher2, Claus Hanusch3, Steffi Busch4, Martin Holländer5, Janine Kreiss-Sender6, Daniela Rezek7, Elisa Flahaut8, Meinolf Karthaus9,10. 1. Gynecological Oncology Practice, Berlin, Germany. 2. Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany. 3. Department of Gynecology, Rotkreuzklinikum München, Munich, Germany. 4. Gynecological Practice, Mühlhausen, Germany. 5. Gynecological Practice, Pirmasens, Germany. 6. Gynecological Oncology Practice, Braunschweig, Germany. 7. Breast Cancer Center Hamburg at Marien-Hospital Wesel, Wesel, Germany. 8. Department of Medical Affairs, RIEMSER Pharma GmbH, Berlin, Germany. 9. Department of Hematology, Oncology and Palliative Care, Klinikum Neuperlach, Munich, Germany. 10. Department of Hematology, Oncology and Palliative Care, Klinikum Harlaching, Munich, Germany.
Abstract
Introduction: In a prospective non-interventional study involving 2,173 patients, we showed that use of the oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg (NEPA) for prevention of chemotherapy (Ctx)-induced nausea and vomiting has beneficial effects on the quality of life (QoL) of patients with various types of cancers receiving highly or moderately emetogenic Ctx. Here, we report on the effects on QoL, effectiveness, and tolerability of NEPA in patients with breast cancer exposed to anthracycline-cyclophosphamide (AC)-based Ctx. Methods: This is a post hoc subanalysis of a prospective non-interventional study in 1,197 patients with breast cancer receiving up to 3 cycles of doxorubicin or epirubicin plus cyclophosphamide and NEPA. NEPA administration was per the summary of product characteristics. Results: In cycle 1 of Ctx, a large proportion of patients (84%) reported "no impact on daily life" (NIDL) due to vomiting; 53% of patients reported NIDL due to nausea. The complete response rate was 86/88/81% in the acute/delayed/overall phase in cycle 1, and NEPA was well tolerated throughout the study. Conclusion: The real-world beneficial effects of NEPA prophylaxis on QoL were confirmed for patients with breast cancer receiving AC. NEPA was effective with a good safety profile in this patient population in clinical practice.
Introduction: In a prospective non-interventional study involving 2,173 patients, we showed that use of the oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg (NEPA) for prevention of chemotherapy (Ctx)-induced nausea and vomiting has beneficial effects on the quality of life (QoL) of patients with various types of cancers receiving highly or moderately emetogenic Ctx. Here, we report on the effects on QoL, effectiveness, and tolerability of NEPA in patients with breast cancer exposed to anthracycline-cyclophosphamide (AC)-based Ctx. Methods: This is a post hoc subanalysis of a prospective non-interventional study in 1,197 patients with breast cancer receiving up to 3 cycles of doxorubicin or epirubicin plus cyclophosphamide and NEPA. NEPA administration was per the summary of product characteristics. Results: In cycle 1 of Ctx, a large proportion of patients (84%) reported "no impact on daily life" (NIDL) due to vomiting; 53% of patients reported NIDL due to nausea. The complete response rate was 86/88/81% in the acute/delayed/overall phase in cycle 1, and NEPA was well tolerated throughout the study. Conclusion: The real-world beneficial effects of NEPA prophylaxis on QoL were confirmed for patients with breast cancer receiving AC. NEPA was effective with a good safety profile in this patient population in clinical practice.
Authors: Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag Journal: JAMA Date: 2017-07-11 Impact factor: 56.272
Authors: Lee S Schwartzberg; Stanley M Marks; Nashat Y Gabrail; Robert B Geller; Jonathan Kish Journal: J Comp Eff Res Date: 2019-05-09 Impact factor: 1.744
Authors: George Dranitsaris; Sasha Mazzarello; Stephanie Smith; Lisa Vandermeer; Nathaniel Bouganim; Mark Clemons Journal: Support Care Cancer Date: 2015-09-17 Impact factor: 3.603
Authors: Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Gary H Lyman Journal: J Clin Oncol Date: 2020-07-13 Impact factor: 44.544